Resting heart rate and the risk of microvascular complications in patients with type 2 diabetes mellitus

Graham S Hillis, Jun Hata, Mark Woodward, Vlado Perkovic, Hisatomi Arima, Clara K Chow, Sophia Zoungas, Anushka Patel, Neil R Poulter, Giuseppe Mancia, Bryan Williams, John Chalmers, Graham S Hillis, Jun Hata, Mark Woodward, Vlado Perkovic, Hisatomi Arima, Clara K Chow, Sophia Zoungas, Anushka Patel, Neil R Poulter, Giuseppe Mancia, Bryan Williams, John Chalmers

Abstract

Background: A higher resting heart rate is associated with an increased probability of cardiovascular complications and premature death in patients with type 2 diabetes mellitus. The impact of heart rate on the risk of developing microvascular complications, such as diabetic retinopathy and nephropathy, is, however, unknown. The present study tests the hypothesis that a higher resting heart rate is associated with an increased incidence and a greater progression of microvascular complications in patients with type 2 diabetes mellitus.

Methods and results: The relation between baseline resting heart rate and the development of a major microvascular event was examined in 11 140 patients who participated in the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) study. Major microvascular events were defined as a composite of new or worsening nephropathy or new or worsening retinopathy. Patients with a higher baseline heart rate were at increased risk of a new major microvascular complication during follow-up (adjusted hazard ratio: 1.13 per 10 beats per minute; 95% confidence interval: 1.07-1.20; P<0.001). The excess hazard was evident for both nephropathy (adjusted hazard ratio: 1.16 per 10 beats per minute; 95% confidence interval: 1.08-1.25) and retinopathy (adjusted hazard ratio: 1.11 per 10 beats per minute; 95% confidence interval: 1.02-1.21).

Conclusion: Patients with type 2 diabetes mellitus who have a higher resting heart rate experience a greater incidence of new-onset or progressive nephropathy and retinopathy.

Clinical trial registration: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00145925. http://www.advance-trial.com/static/html/prehome/prehome.asp.

Keywords: diabetes mellitus, type 2; heart rate; microcirculation.

Figures

Figure 1.
Figure 1.
Prevalence of albuminuria according to fifths of heart rate at baseline.
Figure 2.
Figure 2.
Effects of baseline heart rate on major microvascular events in subgroups. Adjusted for age, sex, randomized treatment for blood pressure, randomized treatment for glucose, body mass index, duration of diabetes, glycosylated hemoglobin, prior macrovascular complication of diabetes (see text), estimated glomerular filtration rate, urinary albumin:creatinine ratio, systolic blood pressure, diastolic blood pressure, history of hospitalization for heart failure, regular exercise (see text), current cigarette smoking, total cholesterol, triglycerides, atrial fibrillation, use of calcium channel antagonists, and use of β-blockers. Where relevant, the variable used for subgrouping was excluded from the model. Centers of boxes are placed at the estimates of adjusted hazard ratio (HR) for each subgroup. Areas of the boxes are proportional to the reciprocal of the variance of the estimates. Horizontal lines represent 95% confidence intervals (CI). Vertical broken lines indicate the estimate of overall adjusted hazard ratio. The widths of diamonds represent 95% CI. bpm indicates beats per minute.

References

    1. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial research group. N Engl J Med. 1993;329:977-986.
    1. Rajala U, Pajunpaa H, Koskela P, Keinanen-Kiukaanniemi S. High cardiovascular disease mortality in subjects with visual impairment caused by diabetic retinopathy. Diabetes Care. 2000;23:957-961.
    1. Klein R, Klein BE, Moss SE, Cruickshanks KJ. Association of ocular disease and mortality in a diabetic population. Arch Ophthalmol. 1999;117:1487-1495.
    1. Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, Halle JP, Young J, Rashkow A, Joyce C, Nawaz S, Yusuf S. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA. 2001;286:421-426.
    1. McClintic BR, McClintic JI, Bisognano JD, Block RC. The relationship between retinal microvascular abnormalities and coronary heart disease: a review. Am J Med. 2010;123:374.e1-374.e7.
    1. Arnlov J, Evans JC, Meigs JB, Wang TJ, Fox CS, Levy D, Benjamin EJ, D'Agostino RB, Vasan RS. Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study. Circulation. 2005;112:969-975.
    1. Klausen K, Borch-Johnsen K, Feldt-Rasmussen B, Jensen G, Clausen P, Scharling H, Appleyard M, Jensen JS. Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes. Circulation. 2004;110:32-35.
    1. Romundstad S, Holmen J, Hallan H, Kvenild K, Ellekjaer H. Microalbuminuria and all-cause mortality in treated hypertensive individuals: does sex matter? The Nord-Trondelag Health Study (HUNT), Norway. Circulation. 2003;108:2783-2789.
    1. Fox K, Borer JS, Camm AJ, Danchin N, Ferrari R, Lopez Sendon JL, Steg PG, Tardif JC, Tavazzi L, Tendera M. Resting heart rate in cardiovascular disease. J Am Coll Cardiol. 2007;50:823-830.
    1. Palatini P. Elevated heart rate in cardiovascular diseases: a target for treatment?. Prog Cardiovasc Dis. 2009;52:46-60.
    1. Hillis GS, Woodward M, Rodgers A, Chow CK, Li Q, Zoungas S, Patel A, Webster R, Batty GD, Ninomiya T, Mancia G, Poulter NR, Chalmers J. Resting heart rate and the risk of death and cardiovascular complications in patients with type 2 diabetes mellitus. Diabetologia. 2012;55:1283-1290.
    1. Bohm M, Reil JC, Danchin N, Thoenes M, Bramlage P, Volpe M. Association of heart rate with microalbuminuria in cardiovascular risk patients: data from i-SEARCH. J Hypertens. 2008;26:18-25.
    1. Bohm M, Thoenes M, Neuberger HR, Graber S, Reil JC, Bramlage P, Volpe M. Atrial fibrillation and heart rate independently correlate to microalbuminuria in hypertensive patients. Eur Heart J. 2009;30:1364-1371.
    1. Ritz E, Viberti GC, Ruilope LM, Rabelink AJ, Izzo JL, Jr, Katayama S, Ito S, Mimran A, Menne J, Rump LC, Januszewicz A, Haller H. Determinants of urinary albumin excretion within the normal range in patients with type 2 diabetes: the Randomised Olmesartan And Diabetes MicroAlbuminuria Prevention (ROADMAP) study. Diabetologia. 2010;53:49-57.
    1. Pfister R, Erdmann E, Schneider CA. Association and prognostic impact of heart rate and micro-albuminuria in patients with type 2 diabetes and cardiovascular disease: results from the PROactive trial. J Atheroscler Thromb. 2011;18:65-71.
    1. Imano E, Miyatsuka T, Motomura M, Kanda T, Matsuhisa M, Kajimoto Y, Yamasaki Y, Hori M. Heart rate elevation and diabetic retinopathy in patients with type 2 diabetes mellitus and normoalbuminuria. Diabetes Res Clin Pract. 2001;52:185-191.
    1. Patel A, MacMahon S, Chalmers J, Neal B, Woodward M, Billot L, Harrap S, Poulter N, Marre M, Cooper M, Glasziou P, Grobbee DE, Hamet P, Heller S, Liu LS, Mancia G, Mogensen CE, Pan CY, Rodgers A, Williams B. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007;370:829-840.
    1. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560-2572.
    1. Study rationale and design of advance: Action in Diabetes and Vascular Disease—Preterax and Diamicron MR Controlled Evaluation. Diabetologia. 2001;44:1118-1120.
    1. Woodward M.Epidemiology: Study Design and Data Analysis. 20052nd ed.Boca Raton, FL: Chapman and Hall/CRC Press; 554-557.
    1. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496-509.
    1. Du X, Ninomiya T, de Galan B, Abadir E, Chalmers J, Pillai A, Woodward M, Cooper M, Harrap S, Hamet P, Poulter N, Lip GY, Patel A. Risks of cardiovascular events and effects of routine blood pressure lowering among patients with type 2 diabetes and atrial fibrillation: results of the ADVANCE study. Eur Heart J. 2009;30:1128-1135.
    1. Fox KM. Current status: heart rate as a treatable risk factor. Eur Heart J. 2011;13suppl CC30-C36.
    1. Brotman DJ, Bash LD, Qayyum R, Crews D, Whitsel EA, Astor BC, Coresh J. Heart rate variability predicts ESRD and CKD-related hospitalization. J Am Soc Nephrol. 2010;21:1560-1570.
    1. Inoue T, Iseki K, Iseki C, Ohya Y, Kinjo K, Takishita S. Heart rate as a risk factor for developing chronic kidney disease: longitudinal analysis of a screened cohort. Clin Exp Nephrol. 2009;13:487-493.
    1. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin Epidemiologic Study of Diabetic Retinopathy, II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol. 1984;102:520-526.
    1. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin Epidemiologic Study of Diabetic Retinopathy, III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol. 1984;102:527-532.
    1. Wong TY, Moss SE, Klein R, Klein BE. Is the pulse rate useful in assessing risk of diabetic retinopathy and macular oedema? The Wisconsin Epidemiological Study of Diabetic Retinopathy. Br J Ophthalmol. 2001;85:925-927.
    1. Ceconi C, Guardigli G, Rizzo P, Francolini G, Ferrari R. The heart rate story. Eur Heart J. 2011;13suppl CC4-C13.
    1. Nakagawa T, Tanabe K, Croker BP, Johnson RJ, Grant MB, Kosugi T, Li Q. Endothelial dysfunction as a potential contributor in diabetic nephropathy. Nat Rev Nephrol. 2011;7:36-44.
    1. Stehouwer CD. Endothelial dysfunction in diabetic nephropathy: state of the art and potential significance for non-diabetic renal disease. Nephrol Dial Transplant. 2004;19:778-781.
    1. Rosenson RS, Fioretto P, Dodson PM. Does microvascular disease predict macrovascular events in type 2 diabetes?. Atherosclerosis. 2011;218:13-18.
    1. Jurca R, Jackson AS, LaMonte MJ, Morrow JR, Jr, Blair SN, Wareham NJ, Haskell WL, van Mechelen W, Church TS, Jakicic JM, Laukkanen R. Assessing cardiorespiratory fitness without performing exercise testing. Am J Prev Med. 2005;29:185-193.
    1. Standards of medical care in diabetes—2008. Diabetes Care. 2008;31suppl 1S12-S54.
    1. Vinik AI, Maser RE, Mitchell BD, Freeman R. Diabetic autonomic neuropathy. Diabetes Care. 2003;26:1553-1579.
    1. Grassi G, Vailati S, Bertinieri G, Seravalle G, Stella ML, Dell'Oro R, Mancia G. Heart rate as marker of sympathetic activity. J Hypertens. 1998;16:1635-1639.
    1. Frattola A, Parati G, Gamba P, Paleari F, Mauri G, Di Rienzo M, Castiglioni P, Mancia G. Time and frequency domain estimates of spontaneous baroreflex sensitivity provide early detection of autonomic dysfunction in diabetes mellitus. Diabetologia. 1997;40:1470-1475.
    1. Weston PJ, James MA, Panerai R, McNally PG, Potter JF, Thurston H, Swales JD. Abnormal baroreceptor-cardiac reflex sensitivity is not detected by conventional tests of autonomic function in patients with insulin-dependent diabetes mellitus. Clin Sci (Lond). 1996;91:59-64.
    1. Carnethon MR, Golden SH, Folsom AR, Haskell W, Liao D. Prospective investigation of autonomic nervous system function and the development of type 2 diabetes: the Atherosclerosis Risk in Communities study, 1987–1998. Circulation. 2003;107:2190-2195.
    1. Lurbe E, Redon J, Kesani A, Pascual JM, Tacons J, Alvarez V, Batlle D. Increase in nocturnal blood pressure and progression to microalbuminuria in type 1 diabetes. N Engl J Med. 2002;347:797-805.
    1. Knudsen ST, Laugesen E, Hansen KW, Bek T, Mogensen CE, Poulsen PL. Ambulatory pulse pressure, decreased nocturnal blood pressure reduction and progression of nephropathy in type 2 diabetic patients. Diabetologia. 2009;52:698-704.
    1. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek ME, Henderson WG, Huang GD. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360:129-139.
    1. Ismail-Beigi F, Craven T, Banerji MA, Basile J, Calles J, Cohen RM, Cuddihy R, Cushman WC, Genuth S, Grimm RH, Jr, Hamilton BP, Hoogwerf B, Karl D, Katz L, Krikorian A, O'Connor P, Pop-Busui R, Schubart U, Simmons D, Taylor H, Thomas A, Weiss D, Hramiak I. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet. 2010;376:419-430.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner